[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-372792-105":59,"doc-detail-372792-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cutaneous-adverse-effects-of-egfr-therapy-in-breast-cancer-treatment","Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment","","Breast cancer is among the most common cancers in U.S. women. Epidermal growth factor receptor inhibitors (EGFRIs) target pathways driving tumor growth but frequently cause dermatologic toxicities that impact quality of life and treatment adherence. This review summarizes the clinical features, mechanisms, and management of EGFRI-related skin adverse effects, based on a PubMed review of 134 studies, with 90 meeting inclusion criteria from 2014 to 2024.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cutaneous-adverse-effects-of-egfr-therapy-in-breast-cancer-treatment/372792/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cutaneous-adverse-effects-of-egfr-therapy-in-breast-cancer-treatment/372792.png","ImageObject",300,407,{"name":92,"@type":93},"kopisore","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-01","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What does the review focus on regarding EGFR therapy in breast cancer?","Question",{"text":112,"@type":113},"The review summarizes clinical features, mechanisms, and management of EGFRI-related skin adverse effects in breast cancer patients.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were studies selected for this review?",{"text":117,"@type":113},"A PubMed search identified 134 studies; 90 were included when they reported data on females treated with EGFRI for active breast cancer and covered cutaneous side effects within 2014–2024.",{"name":119,"@type":110,"acceptedAnswer":120},"What factors influence the severity of skin toxicity?",{"text":121,"@type":113},"Severity is influenced by patient-specific factors such as age, nutrition, lifestyle, genetics, and ethnicity, as well as treatment-related factors including drug dosage and combination therapies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},372792,1790294214,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962090880963,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","Clinical and Translational Science   \n REVIEW  OPEN ACCESS   \nCutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment  \nTvisha Devireddy1  | Clara Lim1 | Jhillika Patel2  | Isabella J. Tan2  | Bernard A. Cohen3   \n1Johns Hopkins University School of Medicine, Baltimore, Maryland, USA | 2Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey,  \nUSA | 3Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA Correspondence: Isabella J. Tan ([ijt11@rwjms.rutgers.edu](ijt11@rwjms.rutgers.edu))  \nReceived: 28 August 2025 | Revised: 6 November 2025 | Accepted: 11 November 2025  \nKeywords: breast cancer | chemotherapy-induced skin toxicity | cutaneous adverse effects | dermatologic management | epidermal growth factor receptor inhibitors | quality of life  \nABSTRACT  \nBreast cancer is among the most common cancers in U.S. women. Epidermal growth factor receptor inhibitors (EGFRIs) target pathways driving tumor growth but frequently cause dermatologic toxicities that impact quality of life and treatment adherence. This review summarizes the clinical features, mechanisms, and management of EGFRI-related skin adverse effects. A comprehensive PubMed search yielded 134 studies that discussed EGFRI treatment in breast cancer patients. Studies were included if they published over the past 10 years (between 2014 and 2024), reported data on females treated with EGFRI for active breast cancer, and included cutaneous side effects. Ninety articles met this inclusion criteria. Findings indicate that the severity of skin toxicity is influenced by patient-specific factors such as age, nutrition, lifestyle, genetics and ethnicity, as well as treatment-related factors including drug dosage and combination therapies. Common toxicities include papulopustular rashes, xerosis, pruritus, alopecia, and severe reactions such as Stevens-Johnson syndrome and toxic epidermal necrolysis. The specific type of EGFRI (monoclonal antibodies or tyrosine kinase inhibitors) also affects the nature of dermatological reactions. Management strategies include prophylactic skin care, symptomatic treatments, and emerging therapies such as laser therapy. Chemotherapy-induced skin toxicities from EGFRI in breast cancer treatment significantly impact patient quality of life and treatment adherence. This study underscores the need for proactive management as well as conversations with patients regarding the cutaneous adverse effects prior to starting EGFR treatment to enhance patient awareness.  \n\n| Abbreviations: AGEP, acute generalized exanthematous pustulosis; AMP, antimicrobial peptide; BSA, body surface area; CCL18, C-C Motif chemokine ligand 18; CCL2, C-C Motif chemokine ligand 2; CCL3, C-C Motif chemokine ligand 3; CCL5, C-C Motif chemokine ligand 5; CINC-2, cytokine-induced neutrophil chemoattractant 2; CINC-3, cytokine-induced neutrophil chemoattractant 3; Cmab, cetuximab; CX3CL1, C-X3-C Motif chemokine ligand 1; CXCL10, C-X-C Motif chemokine ligand 10; CXCL8, C-X-C Motif chemokine ligand 8; CXCL9, C-X-C Motif chemokine ligand 9; CXCR4, C-X-C chemokine receptor type 4; EGF, epidermal growth factor; EGFR, epidermal growth factor receptor; EGFRI, epidermal growth factor receptor inhibitor; GWAS, genome-wide association studies; HER2, human epidermal growth factor receptor 2; HFS, hand-foot syndrome; IL-8, interleukin-8; INCI, international nomenclature of cosmetic ingredients; mAb, monoclonal antibody; NCI-CTCAE, National Cancer Institute Common Terminology Criteria for Adverse Events; NSAID, non-steroidal anti-inflammatory drug; PZH, Pien Tze Huang; QOL, quality of life; rhEGF, recombinant human epidermal growth factor; SCARs, severe cutaneous adverse reactions; SJS, Stevens-Johnson syndrome; TEN, toxic epidermal necrolysis; TKI, tyrosine kinase inhibitor; TREM-1, triggering receptor expressed on myeloid cells 1; XCL1, X-C Motif chemokine ligand 1.\u003Cbr>Tvisha Devireddy and Clara Lim are co first authors.","cbCait4XmRflM4bn","https://ap.wps.com/l/cbCait4XmRflM4bn","pdf",1194210,14,"English","# Introduction\n## Overview of Breast Cancer Treatment\n## Role of EGFR Antagonists in Breast Cancer Treatment\n# Cutaneous Adverse Effects of EGFR Therapy\n## Clinical Features and Mechanisms\n## Management Strategies","[{\"question\":\"What does the review focus on regarding EGFR therapy in breast cancer?\",\"answer\":\"The review summarizes clinical features, mechanisms, and management of EGFRI-related skin adverse effects in breast cancer patients.\"},{\"question\":\"How were studies selected for this review?\",\"answer\":\"A PubMed search identified 134 studies; 90 were included when they reported data on females treated with EGFRI for active breast cancer and covered cutaneous side effects within 2014–2024.\"},{\"question\":\"What factors influence the severity of skin toxicity?\",\"answer\":\"Severity is influenced by patient-specific factors such as age, nutrition, lifestyle, genetics, and ethnicity, as well as treatment-related factors including drug dosage and combination therapies.\"}]","Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment | PDF",1790195404,35]